{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:54:10Z","timestamp":1794020050991,"version":"4.8.0"},"reference-count":46,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Chiesi USA, Inc"},{"name":"Protalix Biotherapeutics, Inc."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2023,9,10]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Pegunigalsidase alfa is a PEGylated \u03b1-galactosidase A enzyme replacement therapy. BALANCE (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02795676\">NCT02795676<\/jats:ext-link>\n                      ) assessed non-inferiority of pegunigalsidase alfa versus agalsidase beta in adults with Fabry disease with an annualised estimated glomerular filtration rate (eGFR) slope more negative than \u22122 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      \/year who had received agalsidase beta for \u22651\u2009year.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomly assigned 2:1 to receive 1\u2009mg\/kg pegunigalsidase alfa or agalsidase beta every 2 weeks for 2 years. The primary efficacy analysis assessed non-inferiority based on median annualised eGFR slope differences between treatment arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy-seven patients received either pegunigalsidase alfa (n=52) or agalsidase beta (n=25). At baseline, mean (range) age was 44 (18\u201360) years, 47 (61%) patients were male, median eGFR was 74.5\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      and median (range) eGFR slope was \u22127.3 (\u221230.5, 6.3) mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      \/year. At 2 years, the difference between median eGFR slopes was \u22120.36\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      \/year, meeting the prespecified non-inferiority margin. Minimal changes were observed in lyso-Gb3 concentrations in both treatment arms at 2 years. Proportions of patients experiencing treatment-related adverse events and mild or moderate infusion-related reactions were similar in both groups, yet exposure-adjusted rates were 3.6-fold and 7.8-fold higher, respectively, with agalsidase beta than pegunigalsidase alfa. At the end of the study, neutralising antibodies were detected in 7 out of 47 (15%) pegunigalsidase alfa-treated patients and 6 out of 23 (26%) agalsidase beta-treated patients. There were no deaths.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on rate of eGFR decline over 2 years, pegunigalsidase alfa was non-inferior to agalsidase beta. Pegunigalsidase alfa had lower rates of treatment-emergent adverse events and mild or moderate infusion-related reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02795676\">NCT02795676<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jmg-2023-109445","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T13:21:01Z","timestamp":1699449661000},"page":"520-530","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":47,"title":["Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study"],"prefix":"10.1136","volume":"61","clinical-trial-number":[{"clinical-trial-number":"nct02795676","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02795676","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02795676","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03566017","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eric L","family":"Wallace","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Nephrology, The University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Goker-Alpan","sequence":"additional","affiliation":[{"name":"Lysosomal and Rare Disorders Research and Treatment Center, Inc, Fairfax, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R","family":"Wilcox","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrl","family":"Holida","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bernat","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Longo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Medical Genetics, University of Utah Health, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3372-7850","authenticated-orcid":false,"given":"Ale\u0161","family":"Linhart","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Charles University and General University Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-9173","authenticated-orcid":false,"given":"Derralynn A","family":"Hughes","sequence":"additional","affiliation":[{"name":"Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust and University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Hopkin","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen, Bergen, Norway"},{"name":"Department of Pediatrics, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Langeveld","sequence":"additional","affiliation":[{"name":"Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n Traslacional. Hospital Universitario Miguel Servet, Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n (IIS Arag\u00f3n), Zaragoza, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER-ISCIII), Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[{"name":"Department of Public Health, Universita degli Studi di Napoli Federico II, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-007X","authenticated-orcid":false,"given":"Dominique Paul","family":"Germain","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, University of Versailles, Garches, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Mehta","sequence":"additional","affiliation":[{"name":"Baylor University Medical Center at Dallas, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B","family":"Deegan","sequence":"additional","affiliation":[{"name":"Lysosmal Disorders Unit, Department of Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Judit","family":"Molnar","sequence":"additional","affiliation":[{"name":"Institute of Genomic Medicine and Rare Disorders, Semmelweis University Clinical Center, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damara","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, UPMC Children\u2019s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jovanovic","sequence":"additional","affiliation":[{"name":"Mark Holland Metabolic Unit, Northern Care Alliance NHS Foundation Trust, Greater Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Muriello","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A","family":"Barshop","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Kimonis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California Irvine, Irvine, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojan","family":"Vujkovac","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, General Hospital Slovenj Gradec, Slovenj Gradec, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4119-5516","authenticated-orcid":false,"given":"Albina","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Clinical Nutrition, University Hospital Zurich and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarekegn","family":"Geberhiwot","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Queen Elizabeth Hospital Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Kantola","sequence":"additional","affiliation":[{"name":"Division of Medicine, Turku University Hospital, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Knoll","sequence":"additional","affiliation":[{"name":"Phoenix Children\u2019s Hospital, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Waldek","sequence":"additional","affiliation":[{"name":"University of Sunderland, Sunderland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khan","family":"Nedd","sequence":"additional","affiliation":[{"name":"Infusion Associates, Grand Rapids, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amel","family":"Karaa","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital for Children, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einat","family":"Brill-Almon","sequence":"additional","affiliation":[{"name":"Protalix Biotherapeutics, Carmiel, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Alon","sequence":"additional","affiliation":[{"name":"Product Development, Protalix Biotherapeutics, Carmiel, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Chertkoff","sequence":"additional","affiliation":[{"name":"Protalix Biotherapeutics, Carmiel, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Rocco","sequence":"additional","affiliation":[{"name":"Chiesi Farmaceutici SpA, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Sakov","sequence":"additional","affiliation":[{"name":"DataSights, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4112-0677","authenticated-orcid":false,"given":"David G","family":"Warnock","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, The University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"2025101710131800000_61.6.520.1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S247814"},{"key":"2025101710131800000_61.6.520.2","unstructured":"Bokhari SRA , Zulfiqar H , Hariz A . Fabry Disease. Treasure Island (FL): StatPearls, 2022."},{"key":"2025101710131800000_61.6.520.3","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-022-02215-x","article-title":"Expert opinion on the recognition, diagnosis and management of children and adults with fabry disease: a multidisciplinary Turkey perspective","volume":"17","author":"Ezgu","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"2025101710131800000_61.6.520.4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016090964"},{"key":"2025101710131800000_61.6.520.5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/TACG.S146022","article-title":"Multiple phenotypic domains of fabry disease and their relevance for establishing genotype- phenotype correlations","volume":"12","author":"Oliveira","year":"2019","journal-title":"Appl Clin Genet"},{"key":"2025101710131800000_61.6.520.6","unstructured":"Mehta A , Hughes DA , et al . Fabry disease. In: Adam MP , Everman DB , Mirzaa GM , eds. GeneReviews((R)). Seattle (WA), 1993."},{"key":"2025101710131800000_61.6.520.7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.gene.2017.10.064","article-title":"Female fabry disease patients and X-Chromosome inactivation","volume":"641","author":"Juchniewicz","year":"2018","journal-title":"Gene"},{"key":"2025101710131800000_61.6.520.8","doi-asserted-by":"publisher","DOI":"10.1111\/cge.12613"},{"key":"2025101710131800000_61.6.520.9","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/ajmg.a.62728","article-title":"Pitfalls of X-Chromosome inactivation testing in females with fabry disease","volume":"188","author":"\u0158eboun","year":"2022","journal-title":"Am J Med Genet A"},{"key":"2025101710131800000_61.6.520.10","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-5-14","article-title":"Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review","volume":"5","author":"Pinto","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"2025101710131800000_61.6.520.11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ymgme.2014.11.005","article-title":"Absence of \u0391-Galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts","volume":"114","author":"Fuller","year":"2015","journal-title":"Mol Genet Metab"},{"key":"2025101710131800000_61.6.520.12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010206","article-title":"Fabry disease therapy: state-of-the-art and current challenges","volume":"22","author":"Azevedo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025101710131800000_61.6.520.13","unstructured":"ELFABRIO (Pegunigalsidase Alfa-Iwxj) injection, for intravenous use. ELFABRIO (Pegunigalsidase Alfa-Iwxj) injection, for intravenous use Ed. Parma, Italy Chiesi Farmaceutici S.p.A; 2023."},{"key":"2025101710131800000_61.6.520.14","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/GIM.0b013e3181f6e676","article-title":"Therapeutic goals in the treatment of fabry disease","volume":"12","author":"Mehta","year":"2010","journal-title":"Genet Med"},{"key":"2025101710131800000_61.6.520.15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ehf2.12647","article-title":"Cardiomyopathy and kidney function in agalsidase beta-treated female fabry patients: a pre-treatment vs. post-treatment analysis","volume":"7","author":"Wanner","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2025101710131800000_61.6.520.16","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2014-102797"},{"key":"2025101710131800000_61.6.520.17","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-022-02392-9","article-title":"Twenty years of the Fabry outcome survey (FOS): insights, achievements, and lessons learned from a global patient registry","volume":"17","author":"Beck","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"2025101710131800000_61.6.520.18","unstructured":"FABRAZYME\u00ae (Agalsidase beta) for injection, for intravenous use. FABRAZYME\u00ae (Agalsidase beta) for injection, for intravenous use ed. Cambridge, MA, USA Genzyme Corporation; 2021."},{"key":"2025101710131800000_61.6.520.19","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.3390\/ijms21165784","article-title":"Predicting the development of anti-drug antibodies against recombinant alpha-galactosidase a in male patients with classical fabry disease","volume":"21","author":"van der Veen","year":"2020","journal-title":"IJMS"},{"key":"2025101710131800000_61.6.520.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2018.11.008"},{"key":"2025101710131800000_61.6.520.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase a in fabry disease on plasma and urinary (Lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"2025101710131800000_61.6.520.22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","article-title":"Fabry disease: the current treatment landscape","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs"},{"key":"2025101710131800000_61.6.520.23","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2006.104026"},{"key":"2025101710131800000_61.6.520.24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.21.2743"},{"key":"2025101710131800000_61.6.520.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107053450102"},{"key":"2025101710131800000_61.6.520.26","doi-asserted-by":"publisher","DOI":"10.1086\/422366"},{"key":"2025101710131800000_61.6.520.27","first-page":"109","article-title":"Severe infusion reactions to fabry enzyme replacement therapy: rechallenge after tracheostomy","volume":"5","author":"Nicholls","year":"2012","journal-title":"JIMD Rep"},{"key":"2025101710131800000_61.6.520.28","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1021\/acs.bioconjchem.8b00133","article-title":"Development and analytical characterization of pegunigalsidase alfa, a chemically cross-linked plant recombinant human alpha-galactosidase-a for treatment of fabry disease","volume":"29","author":"Ruderfer","year":"2018","journal-title":"Bioconjug Chem"},{"key":"2025101710131800000_61.6.520.29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","article-title":"Characterization of a chemically modified plant cell culture expressed human \u03b1-galactosidase-a enzyme for treatment of fabry disease","volume":"114","author":"Kizhner","year":"2015","journal-title":"Mol Genet Metab"},{"key":"2025101710131800000_61.6.520.30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","article-title":"Pegunigalsidase alfa, a novel pegylated enzyme replacement therapy for fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year phase 1\/2 clinical trial","volume":"42","author":"Schiffmann","year":"2019","journal-title":"J Inherit Metab Dis"},{"key":"2025101710131800000_61.6.520.31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.omtm.2022.07.009","article-title":"Pre-existing anti-drug antibodies in fabry disease show less affinity for pegunigalsidase alfa","volume":"26","author":"Lenders","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025101710131800000_61.6.520.32","unstructured":"Replagal\u00ae (agalsidase alfa) . Replagal\u00ae (agalsidase alfa) ed. Dublin, Ireland: Takeda Pharmaceuticals, 2022."},{"key":"2025101710131800000_61.6.520.33","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.33963\/KP.a2021.0139","article-title":"Anderson-Fabry disease: no histological signs of pathological accumulation in arterial and venous endothelium during pegunigalsidase alfa therapy","volume":"79","author":"Dost\u00e1lov\u00e1","year":"2021","journal-title":"Kardiol Pol"},{"key":"2025101710131800000_61.6.520.34","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"2025101710131800000_61.6.520.35","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2015-103471"},{"key":"2025101710131800000_61.6.520.36","doi-asserted-by":"publisher","DOI":"10.1021\/ac404000d"},{"key":"2025101710131800000_61.6.520.37","first-page":"17","article-title":"Tandem mass spectrometry quantitation of Lyso-Gb3 and six related analogs in plasma for fabry disease patients","volume":"90","author":"Boutin","year":"2016","journal-title":"Curr Protoc Hum Genet"},{"key":"2025101710131800000_61.6.520.38","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/ckj\/sfaa065","article-title":"Agalsidase beta treatment SLOWS estimated glomerular filtration rate loss in classic fabry disease patients: results from an individual patient data meta-analysis","volume":"14","author":"Ortiz","year":"2021","journal-title":"Clin Kidney J"},{"key":"2025101710131800000_61.6.520.39","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-2-200701160-00148"},{"key":"2025101710131800000_61.6.520.40","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp031"},{"key":"2025101710131800000_61.6.520.41","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.ASN.0000016683.73778.78","article-title":"Natural history and treatment of renal involvement in fabry disease","volume":"13 Suppl 2","author":"Branton","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2025101710131800000_61.6.520.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00305-X"},{"key":"2025101710131800000_61.6.520.43","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/mt.2015.87","article-title":"Coformulation of a novel human \u03b1-galactosidase a with the pharmacological chaperone AT1001 leads to improved substrate reduction in fabry mice","volume":"23","author":"Xu","year":"2015","journal-title":"Mol Ther"},{"key":"2025101710131800000_61.6.520.44","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.271"},{"key":"2025101710131800000_61.6.520.45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054548","article-title":"Enzyme replacement therapy for FABRY disease: possible strategies to improve its efficacy","volume":"24","author":"Iacobucci","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025101710131800000_61.6.520.46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European expert consensus statement on therapeutic goals in fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol Genet Metab"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmg-2023-109445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:13:27Z","timestamp":1760721207000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmg-2023-109445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,21]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/jmg-2023-109445"],"URL":"https:\/\/doi.org\/10.1136\/jmg-2023-109445","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]}}}